Evidence map›Paper›PMID 36061558›Full record

SynthesisFrontiers in cardiovascular medicine2022

Using human induced pluripotent stem cell-derived cardiomyocytes to understand the mechanisms driving cardiomyocyte maturation.

Homa Hamledari, Parisa Asghari, Farah Jayousi, Alejandro Aguirre, Yasaman Maaref, Tiffany Barszczewski, Terri Ser, Edwin Moore, Wyeth Wasserman, Ramon Klein Geltink and 2 more

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Single-cell Technology in Stem Cell Research.Current stem cell research & therapy · 2025
    Review
  7. Novel, low-cost bioreactor forFrontiers in bioengineering and biotechnology · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Homa HamledariDepartment of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada.
Parisa AsghariDepartment of Cellular and Physiological Sciences, University of British Colombia, Vancouver, BC, Canada.
Farah JayousiDepartment of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada.
Alejandro AguirreDepartment of Medical Genetics, University of British Colombia, Vancouver, BC, Canada.
Yasaman MaarefDepartment of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada.
Tiffany BarszczewskiDepartment of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada.
Terri SerBC Children's Hospital Research Institute, Vancouver, BC, Canada.
Edwin MooreDepartment of Cellular and Physiological Sciences, University of British Colombia, Vancouver, BC, Canada.
Wyeth WassermanDepartment of Medical Genetics, University of British Colombia, Vancouver, BC, Canada.
Ramon Klein GeltinkBC Children's Hospital Research Institute, Vancouver, BC, Canada.
Sheila TevesDepartment of Biochemistry and Molecular Biology, University of British Colombia, Vancouver, BC, Canada.
Glen F TibbitsDepartment of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular diseases are the leading cause of mortality and reduced quality of life globally. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provide a personalized platform to study inherited heart diseases, drug-induced cardiac toxicity, and cardiac regenerative therapy. However, the immaturity of CMs obtained by current strategies is a major hurdle in utilizing hiPSC-CMs at their fullest potential. Here, the major findings and limitations of current maturation methodologies to enhance the utility of hiPSC-CMs in the battle against a major source of morbidity and mortality are reviewed. The most recent knowledge of the potential signaling pathways involved in the transition of fetal to adult CMs are assimilated. In particular, we take a deeper look on role of nutrient sensing signaling pathways and the potential role of cap-independent translation mediated by the modulation of mTOR pathway in the regulation of cardiac gap junctions and other yet to be identified aspects of CM maturation. Moreover, a relatively unexplored perspective on how our knowledge on the effects of preterm birth on cardiovascular development can be actually utilized to enhance the current understanding of CM maturation is examined. Furthermore, the interaction between the evolving neonatal human heart and brown adipose tissue as the major source of neonatal thermogenesis and its endocrine function on CM development is another discussed topic which is worthy of future investigation. Finally, the current knowledge regarding transcriptional mediators of CM maturation is still limited. The recent studies have produced the groundwork to better understand CM maturation in terms of providing some of the key factors involved in maturation and development of metrics for assessment of maturation which proves essential for future studies on

Indexed as

cell signalinghiPSC-derived cardiomyocytemTOR pathwaypreterm hearttranscriptional regulation

Identifiers

PMID36061558
PMCPMC9429949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.